Following the results of the KATHERINE study, T-DM1 was also approved for patients with HER2-positive BC with residual disease after neoadjuvant therapy [38] and has been evaluated in other HER2-positive solid tumors [39, 40]. This evidence concerns the gene ERBB2 and breast cancer.